All News
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we have seen phase 2 results for CPL’116, and a simultaneous publication in The Lancet Rheumatology.
Read Article
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases.
Read Article
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow
#EULAR2025 #OP0033 https://t.co/nEiTWQEqsP
Dr. John Cush RheumNow ( View Tweet)
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD.
#EULAR2025 @RheumNow https://t.co/HC0skwUKQG
Dr. John Cush RheumNow ( View Tweet)
FDA adds new warning for "myocarditis" to the Pfizer and Moderna COVID-19 vaccines (prev mainly assoc w/ Moderna) - risk is 8 per 1 million people for those on 2023-2024 COVID shots, most common in males ages 12 to 24. Generally good outcomes seen. https://t.co/QZbTRaKGH1 https://t.co/1cAUw73eqF
Links:
Dr. John Cush RheumNow ( View Tweet)
Jekyll and Hyde: which RA-ILD is it?
Dr. David Liew reports on abstract OP0329 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/oH9nXaKRDz https://t.co/iUAJk2Q856
Dr. John Cush RheumNow ( View Tweet)
Prospective KORAIL study of 138 RA pts w/ ILD on chest CT -60% had UIP ILD. After F/U of 2.9 yrs, 35% had RA-ILD progression. Baseline predictors of progression = UIP, ILD >10 %, DLCO %pred, CCP+, KL-6 levels, RA Dz activity. Useful to ID high-risk RA-ILD pts.
Dr. John Cush RheumNow ( View Tweet)
Aortic aneurysms w/ GCA. TriNetX study of 7,294 Bx-proven GCA vs 265,948 controls w/ tension HA. GCA had signif higher 5-yr risk of aortic aneurysms (3.59%; aHR 1.98), including thoracic thoracoabdominal & abdominal. Carotid A stenosis also incr in GCA (aHR 1.59) https://t.co/15fwlHa0FG
Dr. John Cush RheumNow ( View Tweet)
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. https://t.co/tgfsU3uFVo
Dr. John Cush RheumNow ( View Tweet)
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the https://t.co/JgmfxGa6TY
Dr. John Cush RheumNow ( View Tweet)
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 4 Report
Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush RheumNow ( View Tweet)
New ideas in gout management
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX
Dr. John Cush RheumNow ( View Tweet)
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 https://t.co/jPAai9FLkb
Dr. John Cush RheumNow ( View Tweet)
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/M6uU6i5cW4
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis at Risk for Interstitial Lung Disease
A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD).
https://t.co/2zuxF1PY3Q. https://t.co/Icck4qE76X
Dr. John Cush RheumNow ( View Tweet)
#CAR-T in active #scleroderma #diffuse
open label
@sclerodermaUM presented improvement in
#nailfold #capillary patterns
Suggesting #vascular recovery
Hope is for lungs, skin and survival to improve but
These are ▶️
Early days ?risk
OP0338
#EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk
Janet Pope Janetbirdope ( View Tweet)
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA?
🔹️245 pts
🔹️CRP recorded for past 5y
🔹️sustained high CRP in 40%
🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis
POS0714
#EULAR2025
@RheumNow https://t.co/jAlj3sr95H
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Manifestations of relapsing polychondritis
@Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
